The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043).
 
Hiroyuki Nomura
No Relationships to Disclose
 
Daisuke Aoki
Honoraria - AstraZeneca Japan; Chugai Pharma
Consulting or Advisory Role - AstraZeneca Japan; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Hirofumi Michimae
No Relationships to Disclose
 
Mika Mizuno
No Relationships to Disclose
 
Hidekatsu Nakai
No Relationships to Disclose
 
Masahide Arai
No Relationships to Disclose
 
Motoi Sasagawa
No Relationships to Disclose
 
Kimio Ushijima
No Relationships to Disclose
 
Toru Sugiyama
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
 
Motoaki Saito
No Relationships to Disclose
 
Hideki Tokunaga
No Relationships to Disclose
 
Kohei Omatsu
No Relationships to Disclose
 
Toru Nakanishi
No Relationships to Disclose
 
Yoh Watanabe
No Relationships to Disclose
 
Toshiaki Saito
No Relationships to Disclose
 
Nobuo Yaegashi
No Relationships to Disclose